Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande
July 20, 2023 01:30 ET
|
CROSSJECT
Communiqué de presse Crossject signe un nouvel accord de licence pour le traitement dans la crise d'épilepsie pour ZENEO® Midazolam avec AFT Pharmaceuticals pour l'Australie et la Nouvelle-Zélande ...
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
July 19, 2023 06:00 ET
|
Catalyst Pharmaceuticals, Inc.
Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy Synergistic Novel Asset Leverages Catalyst's Expertise and Bolsters...
NeuroSigma Establishes Singapore Subsidiary
July 12, 2023 11:00 ET
|
NeuroSigma, Inc.
LOS ANGELES, July 12, 2023 (GLOBE NEWSWIRE) -- NeuroSigma, Inc. (“NeuroSigma”) today announced the launch of NeuroSigma Pte, Ltd., a Singapore corporation (“NeuroSigma Singapore”), representing...
Baylor Genetics Announces Epilepsy Panel
July 11, 2023 10:01 ET
|
Baylor Genetics
HOUSTON, July 11, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of an...
Neurostimulation Devices Market revenue to hit USD 34 Billion by 2035, says Research Nester
July 11, 2023 07:00 ET
|
Research Nester
New York, July 11, 2023 (GLOBE NEWSWIRE) -- The global neurostimulation devices market is expected to grow at a CAGR of ~12% from 2023 to 2035. The market is estimated to garner a revenue of ~USD 34...
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
June 15, 2023 11:05 ET
|
Neurona Therapeutics
Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the first patient to receive NRTX-1001, memory improvements, and seizure-freedom since seven-months...
Praxis Precision Medicines to Present at the 2023 Jefferies Healthcare Conference
June 02, 2023 09:00 ET
|
Praxis Precision Medicines, Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 11, 2023 07:30 ET
|
Praxis Precision Medicines, Inc.
Ulixacaltamide essential tremor End-of-Phase 2 meeting with FDA scheduled for June 2023 PRAX-628 Phase 1 study results support preclinical profile indicating potential for best-in-class-efficacy for...
Praxis Precision Medicines Announces Positive Topline Results from PRAX-628 Phase 1 Study Enabling Best-in-Class Profile
May 11, 2023 06:55 ET
|
Praxis Precision Medicines, Inc.
PRAX-628 demonstrated a favorable safety and tolerability profile in healthy volunteers at concentrations more than 15-fold the MES EC50; PRAX-628 predicted therapeutic range at least 3-fold wider...
Catalyst Pharmaceuticals Reports Record First Quarter 2023 Results, Achieving 98% Total Revenue Growth Year-over-Year
May 10, 2023 16:27 ET
|
Catalyst Pharmaceuticals, Inc.
Reports Record Total Revenues of $85.4 Million for Q1 2023 Delivers Revenue Growth of 98%, a Record Increase YoY GAAP EPS Diluted of $0.26 Per Share; a 117% Increase YoY Non-GAAP EPS Diluted of...